A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
for
Ulcerative Colitis
Location: London, Fresh Meadows NY, Montreal, Monroe NC,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT06979336
Phase2, Recruiting
Featured
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
for
Neoplasms
Location: New Haven CT, Toronto, Sarasota FL, Houston TX,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06884618
Phase1, Recruiting
Featured
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
for
Von Willebrand Disease, Type 3
Location: Montreal, Richmond VA, Toronto, Gainesville FL,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 0+
Code: NCT06998524
Phase3, Recruiting
Featured
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
for
Ulcerative Colitis
Location: Morristown NJ, Philadelphia PA, Miami FL, Pittsburgh PA,
Sponsor: AbbVie
Sex: All
Age: 2 - 17
Code: NCT07071519
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
for
Breast Cancer
Location: Boston MA, East Patchogue NY, The Bronx NY,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT07100106
Phase1, Phase2, Recruiting
Featured
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
for
Atherosclerosis
Location: New Haven CT, North Massapequa NY, Chapel Hill NC,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT07448038
Phase2, Recruiting
Featured
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
for
Hepatitis C Virus (HCV)
Location: Toronto, Vancouver
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07419347
Recruiting
Featured
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
for
Ventral Hernia
Location: Hershey PA, Wilmington NC, Miami FL, Roanoke VA,
Sponsor: AbbVie
Sex: All
Age: 18 - 70+
Code: NCT07226791
Phase2, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for
Breast Cancer
Location: Moncton, The Bronx NY, New York NY, East Brunswick NJ,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06790693
Phase3, Recruiting
Featured
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
for
Crohn's Disease
Location: Waltham MA, New York NY, Morristown NJ, Orlando FL,
Sponsor: AbbVie
Sex: All
Age: 2 - 17
Code: NCT05995353
Phase3, Recruiting
Featured
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
for
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Location: Boston MA, Albany NY, Virginia Beach VA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06806033
Phase2, Recruiting
Featured
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
for
Neovascular Age-related Macular Degeneration
Location: Hickory NC, Austin TX
Sponsor: Genentech, Inc.
Sex: All
Age: 50+
Code: NCT04853251
Recruiting
Featured
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
for
Chronic Migraine
Location: Nashua NH, Philadelphia PA, Miami FL, Weston FL,
Sponsor: AbbVie
Sex: All
Age: 12 - 17
Code: NCT06810505
Phase3, Recruiting
Featured
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
for
Cancer
Location: Toronto
Sponsor: Hoffmann-La Roche
Sex: All
Age: 0+
Code: NCT05862285
Phase3, Recruiting
Featured
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
for
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment,
Location: Morrisville NC
Sponsor: AbbVie
Sex: Female
Age: 0+
Code: NCT04846959
Recruiting
Featured
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
for
Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Location: St. John's, Moncton, Kingston, Greater Sudbury,